Enanta Pharma (ENTA) Misses Q2 EPS by 5c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.05 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• Bristow Group to acquire Berry Aviation for $105 million